Microglia contributes significantly to brain tumor mass, particularly in astrocytic gliomas. Here, we examine the cytotoxic effects of soluble components secreted from microglia culture on glioma cells. Microglia conditioned culture medium (MCM) actively stimulated apoptotic death of glioma cells, and the effects of MCM prepared from LPS-or IFN-γ-activated microglia were more pronounced. The cytotoxic effects were glioma-specific in that primary cultured rat astrocytes were not affected by MCM. A donor of peroxynitrite induced glioma-specific cell death. In addition, NO synthase inhibitor suppressed glioma cell death induced by activated MCM, indicating that NO is one of the key molecules responsible for glioma cytotoxicity mediated by activated MCM. However, since unstimulated resting microglia produces low or very limited level of NO, MCM may contain other critical molecule(s) that induce glioma apoptosis. To identify the proteins secreted in MCM, proteomic analysis was performed on control or activated medium. Among over 200 protein spots detected by Coomassie blue staining, we identified 26 constitutive and 28 LPS-or IFN-γregulated MCM proteins. Several cathepsin proteases were markedly expressed, which were reduced upon activation. In particular, suppression of cathepsin B by the chemical inhibitors significantly reversed MCMinduced glioma cell death, implying a critical role of this protease in cytotoxicity. Our findings provide evidence on the functional implications of specific microglial-secreted proteins in glioma cytotoxicity, as well as a basis to develop a proteomic databank of both basal and activation-related proteins in microglia.
Introduction
Malignant gliomas are among the most fatal cancer types. In addition to neoplastic cells, the tumor microenvironment comprises nonmalignant cells, such as lymphocytes, astrocytes, endothelial cells, microglia, and macrophages, which influence cancer growth and therapeutic efficacy. Significant macrophage and microglia infiltration in both human and animal brain tumors has been consistently reported [1] [2] [3] [4] , and there is compelling evidence that microglia play an active role in glioma development [2, 5] . However, the involvement of microglia in controlling the growth and infiltration of tumor cells remains a topic of controversy. Microglial cells are present in both the necrotic areas of brain tumor and intact tumor tissue of astrocytic gliomas, supporting a potential role in tumor promotion [6] . On the other hand, microglial secretory compounds may inhibit glioma development via suppression of glioma cell growth [7] . In this case, the biological success of glioma indicates that natural microglial defense mechanisms do not function properly. For example, gliomainfiltrating microglia's anti-tumor activity is limited by characteristic down-regulation of microglial peripheral benzodiazepine receptor. Microglial activity possibly depends on the type of tumor, immune status, or interactions with other cells in the brain.
Peroxynitrite, a highly reactive molecule formed by the neardiffusion reaction of nitric oxide (NO) and superoxide anion, is one of the most potent neurotoxic agents targeting both neurons and glial cells [8, 9] . While astrocytes are relatively more resistant to oxidative injury than neurons due to the high level of intracellular oxidants, including glutathione [10] , several investigators report that peroxynitrite exerts cytotoxic effects on astrocytes at submillimolar concentrations in cultured cells [11] [12] [13] . In contrast, several conflicting studies show that peroxynitrite displays cytoprotective effects depending on its concentration, cell type, and the oxidative states [14] [15] [16] .
Proteomic analysis is one the most powerful methods for the identification of secretory proteins [17, 18] . In the present study, we employed the proteomic approach to obtain an unbiased overview of the proteins secreted by microglia cultures. Notably, cathepsin proteins are abundant in the supernatant fractions of microglia culture. Accumulating evidence shows that intracellular and extracellular proteases of microglia contribute to various events in the central nervous system (CNS) through both nonspecific and limited proteolysis. Cathepsin B specifically exerts cytotoxic effects in the CNS. Microglia-secreted cathepsin B plays an important role in Aβ-induced neuronal apoptosis [19] . Moreover, in slice cultures from rodents and in vivo studies on primates, selective cathepsin B inhibitors protect against ischemia-induced neuronal damage [20] , which is partly mediated by inflammatory and immunological reactions [21] .
Here, we show that microglia induce apoptosis of glioma cells via the release of NO and cathepsin B protease. Our findings collectively indicate that the initiation or development of gliomas may be constitutively monitored by neighboring microglia cells via release of these factors, and breakdown of this balance is associated with tumor progression. Thus, effective regulation of microglia recruitment or activation may contribute to the successful therapeutic targeting of brain neoplasms.
Materials and methods

Reagents
Bacterial lipopolysaccharide (LPS), thrombin, propidium iodide (PI), 4′6-diamidino-2-phenylindole (DAPI), 3-morpholinosydnonimine (SIN-1), N G -monomethyl-l-arginine (l-MMNA), 4-(2-aminoethyl) benzenesulfonylfluoride (AEBSF), trans-epoxysuccinyl-leucylamido (4-guanidino)butane (E-64), pepstatin, N-acetyl-L-leucyl-L-leucyl-Lnorleucinal (LLnL), and cathepsin B were purchased from Sigma Chemical Company. CA-074me (Calbiochem) and Z-Val-Ala-Asp-FMK (zVAD-fmk) (Enzyme Systems Products) were obtained from local suppliers.
Cell cultures
The murine BV2 cell line has been used as a suitable model for in vitro studies of activated microglial cells [22] . It has been verified that the behavior of the BV2 microglial cell line closely mimics that of microglia cells in primary culture [22, 23] . BV2 cells were maintained at 37°C at 5% CO 2 in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated endotoxin-free fetal bovine serum (FBS) (Hyclone), 2 mM glutamine, 100 μg/ml streptomycin, and 100 U/ml penicillin. U373-MG and U87-MG human glioma [24] and C6 rat glioma cell lines were cultured in DMEM medium and CRT-MG human glioma cells [25] were cultured in RPMI-1640 medium, each supplemented with 10% FBS, streptomycin, and penicillin.
Preparation of primary astrocytes and microglia
Primary microglia were prepared from 1-day-old Sprague Dawley rats as described previously, with some modifications [22] . In brief, animals were sacrificed by decapitation, the cerebral cortex was aseptically isolated, and the meninges were carefully removed. The tissue was dissociated in 0.25% trypsin in PBS. Cells were triturated into single cells in MEM containing 10% FBS, and plated on MEM supplemented with 2 mM L-glutamine, 33 mM glucose, 3 mM NaHCO 3 , 10 mM HEPES, and 10% FBS for 10-14 days. To prepare microglia, cells were removed from the T75-flasks by mild shaking at 200 rpm for 2 h [26] . Enriched microglia were nearly pure (N95%), as evident from immunocytochemical staining for a microglia-specific marker, the CR3 complement receptor, detected using the OX-42 antibody (Roche Diagnostics). Astrocytes remaining in T75 flasks after removal of microglia were harvested with 0.1% trypsin. Astrocytes were subcultured twice to ensure sufficient purity for experiments. Astrocyte purity was confirmed by staining for specific glial fibrillary acidic protein (GFAP) (usually N99%). All experiments were carried out in accordance with "The Guidelines for Animal Research at Inha University School of Medicine".
Preparation of microglia conditioned culture medium
For conditioned medium transfer, primary cultured rat or BV2 mouse microglial cells were plated and either left untreated or stimulated with LPS, IFN-γ, or thrombin. Cell-free supernatant fractions were collected after 24-72 h of treatment, and applied to primary astrocytes or various glioma cell lines.
MCM for proteomic analysis was prepared as follows: cells were grown at 1.2 × 10 7 /cells/140 cm 2 , washed three times with PBS, and cultured in serum-free medium containing either LPS or IFN-γ. After 24 h, conditioned culture medium was collected by centrifugation, and passed through a 0.2 μm pore membrane filter (Millipore). Medium was concentrated with a centrifugal concentrator (Centriprep P-10; Millipore), and precipitated with 10% (v/v) TCA for 4 h at 4°C. The pellet was washed with ethanol, and resuspended in urea buffer (7 M urea, 2 M thiourea, 40 mM Tris, 4% CHAPS, 0.5% carrier [Resolyte pH 3.5-10] ampholytes, 15 mM DTT, 1 mM EDTA, 1 mM PMSF, 2% protease inhibitor cocktail, 0.008% bromophenol blue) for 2-D (0.4 mg/gel) gel analysis.
Cell viability
Cells were grown in 24-well plates at a concentration of 5 × 10 4 cells/2 cm 2 followed by proper treatment. Morphological change was examined under the upright type phase-contrast microscopy (Olympus). Fifty microliters of 5 mg/ml 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrasolium bromide (MTT) (Sigma-Aldrich) in growth medium were added to each well. After incubation for 4 h at 37°C with MTT, cell medium was removed. The precipitated formazan, a product of MTT tetrazolium ring by the action of mitochondrial dehydrogenases, was solubilized with dimethyl sulfoxide and quantified spectrophotometrically at 540 nm.
Nitrite assay
NO production was determined by measuring the amount of nitrite, a relatively stable oxidation product of NO, as described previously [22] . In brief, an aliquot of the conditioned culture medium was mixed with an equal volume of 1% sulfanilamide in water and 0.1% N-1-naphthylethylenediamine dihydrochloride in 5% phosphoric acid. The absorbance was determined at 540 nm. Sodium nitrite was used to generate a standard curve.
Apoptosis assay by DAPI staining
DAPI staining was performed as reported previously [26] , with some modifications. In brief, attached cells were washed with PBS, and fixed with 4% PBS-buffered paraformaldehyde solution for 30 min at RT. Fixing solution was removed, and cells were washed with PBS. Cells were treated with pure 0.5% Triton X-100 in PBS, and incubated for 15 min. Next, cells were rinsed with PBS for 5 min, and stained with 1 μg/ml DAPI in the dark for 30 min. Following rinsing with PBS and mounting on glass slides, at least 300 cells per condition were subjected to examination using a fluorescence photomicroscope (Carl Zeiss). Apoptotic cells were identified on the basis of morphology, as well as condensation and fragmentation of nuclei.
Flow cytometric analysis of the cell cycle
Cell cycle analysis was performed as reported previously [27] , with some modifications. For cell cycle analysis, 1 × 10 6 BV2 cells were washed twice with PBS. Cells were fixed with 70% ethanol at − 20°C for at least 12 h. After two washes with PBS, cells were incubated in RNase A/PBS (100 μg/ml) at 37°C for 30 min. Intracellular DNA was labeled with PI (50 μg/ml) for 30 min on ice protected from light, and analyzed with a FACSCalibur fluorescence-activated cell sorter (FACS) (Becton Dickinson).
Immunoblotting
Prepared cells were resuspended in lysis buffer (10 mM Tris, 140 mM NaCl, 1% Triton, 0.5% SDS, and protease inhibitors, pH 8.0) and cleared from cellular debris by centrifugation. Protein samples (20 μg for regular Western and 40 μg for 2-D Western blotting) were separated by SDS-PAGE and transferred to Hybond™-ECL™ membrane (Amersham Biosciences). The membrane was blocked with 5% BSA in TBST solution (10 mM Tris-HCl, pH 8.0, containing 150 mM NaCl and 0.5% Tween 20) . Blots were incubated with human PARP (BD Pharmingen), iNOS (BD Pharmingen), apolipoprotein E (Santa Cruz Biotechnology), cathepsin A (R&D Systems), cathepsin B (Abcam), cathepsin D (Abcam), cathepsin L (R&D Systems), or HSP60 (Abcam). Membranes were washed, incubated with diluted HRP-conjugated secondary antibodies (Amersham Biosciences), and developed by the enhanced chemiluminescence (ECL) detection system (Amersham Biosciences).
2-D image analysis and MALDI-MS
2-D of prepared MCM and MALDI-MS analysis were performed as reported previously, with some modifications [28] . In brief, 400 mg of secreted protein were applied to a 13 cm immobilized nonlinear gradient strip (pH 3-10) (Amersham Biosciences), and focused at 8000 V within 3 h. Second-dimension separation was performed using 12% polyacrylamide gels (chemicals from Serva and Bio-Rad). 2-D gels were stained with colloidal Coomassie blue (Invitrogen) or silver nitrate for 24 h, and destained with deionized water. ImageMaster™ software (Amersham Biosciences) was applied for image analysis of 2-D gels. Protein spots in control MCM and those displaying altered secretion patterns in the presence of LPS or IFN-γ were subjected to MALDI-MS for identification.
For MALDI-MS analysis, protein spots in 2-D gels were excised, destained with 50% acetonitrile in 0.1 M ammonium bicarbonate, and dried in a Speedvac evaporator. Dried gel pieces were reswollen with 30 μl of 25 mM sodium bicarbonate, pH 8.8, containing 50 ng trypsin (Promega, Madison) at 37°C overnight. α-Cyano 4 hydroxycinnamic acid (Bruker Daltonics) (20 mg) was dissolved in 1 ml acetone: ethanol (1:2, v/v), and 0.5 μl matrix solution was mixed with an equivalent volume of sample. The sample was analyzed using an Ultraflex TOF/TOF system (Bruker Daltonics). Peptide masses were matched with the theoretical peptide masses of proteins from all species in the Mascot database.
Statistical analysis
Data are expressed as means ± SEM, and analyzed for statistical significance using analysis of variance (ANOVA) followed by Scheffe's test for multiple comparison. A p value of b 0.05 was considered significant.
Results
Microglia conditioned culture medium (MCM) decreases glioma cell viability and activated MCM is more potent in inducing glioma cell death
We investigated the effects of BV2 microglia conditioned culture medium (MCM) on proliferation or survival of astrocytes and glioma. Conditioned culture media prepared from primary cultured rat microglia or murine BV2 cell line were incubated with rat primary astrocytes or CRT-MG human astrocytic glioma cells. Cell viability was measured with the MTT assay at 72 h. Transfer of MCM prepared from BV2 or primary microglia markedly reduced the viability of CRT-MG cells. In contrast, astrocytes were not significantly influenced by MCM ( Fig. 1A) . Rather, MCM consistently induced low-level proliferation of astrocytes (Figs. 1A and C and 2F). We additionally examined cell status and morphological changes after MCM treatment ( Fig. 1B ). Incubation of astrocytes or CRT-MG cells with MCM of BV2 and primary cultured rat microglial cells for 72 h triggered a dramatic decrease in glioma numbers and morphological changes into elongated shape followed by detaching from plates but no significant changes of astrocytes in terms of both cell number and phenotype.
To determine the influence of MCM prepared from activated microglia, BV2 cells were treated with the well-characterized immune stimulants bacterial lipopolysaccharide (LPS), thrombin, or IFN-γ [22, 23, 29] , followed by collection of MCM. MCM consistently exerted cytotoxic effects on CRT-MG cells. Moreover, LPS-stimulated MCM of BV2 or primary microglia had a more potent effect in a dosedependent manner (Fig. 1C and Suppl. Fig. 1 ). In comparison, astrocytes were not influenced by MCM, and minimally affected by activated MCM. LPS, administered directly at equivalent doses, did not affect cell viability or proliferation of CRT-MG or astrocytes. The influences of residual LPS in activated MCM were tested. Co-treatment with LPS (1, 5, or 10 ng/ml) and MCM did not significantly change the cytotoxic effects of MCM alone (Suppl. Fig. 2 ).
Activated MCM prepared from LPS-, thrombin-, or IFN-γ-stimulated BV2 cells exerted potent cytotoxic effects on CRT-MG survival to a similar extent (data not shown). Next, we examined the effects of MCM and activated MCM on several other rat (C6) or human (U87-MG and U373-MG) glioma cell lines. As expected, MCM induced cytotoxicity in C6, U87-MG, and U373-MG cells and activated MCM ( Fig. 1D ) exerted more significant cytotoxicity, indicating that these effects on glioma cells are general rather than cell type-specific.
MCM and activated MCM trigger apoptosis of glioma cells
Cells were then subjected to DAPI staining, which revealed chromatin condensation, a hallmark of apoptosis. Incubation of CRT-MG with MCM showed condensed nuclei, and incubation with activated MCM gave rise to condensed nuclei with evidence of DNA fragmentation ( Fig. 2A ). MCM and activated MCM prepared from rat primary microglia also induced nuclei condensation and DNA fragmentation in CRT-MG cells (data not shown). This apoptotic characteristic was confirmed by cell cycle analysis. Cells were treated with propidium iodide and the percent of sub-G1 phase, characterized as fragmented DNA, was determined by FACS analysis. Treatment of MCM resulted in 9.54% of cells entering the sub-G1 phase, which is an indicator of apoptosis, and this proportion increased to 22.72% for cells treated with activated MCM (Fig. 2B ). Moreover, PARP cleavage, the final stage marker of apoptosis, was observed at 24 h in BV2 cells and rat primary microglia incubated with MCM or activated MCM ( Fig. 2C) .
To further verify MCM-induced apoptotic death, we treated the MCM-treated CRT-MG glioma cells with the general apoptosis inhibitor zVAD-fmk and examined whether the apoptosis was blocked. zVAD-fmk (1, 10, or 100 μM) was incubated with or without MCM to treat glioma cells. Observing under a light microscope, MCMinduced cell death was almost completely blocked by zVAD-fmk ( Fig.  2D ). While zVAD-fmk itself exerted dose-dependent cytotoxicity (about 15% cell death at 10 μM), MCM-triggered apoptosis was significantly suppressed, as measured with the MTT assay ( Fig. 2E ). However, zVAD-fmk alone had no significant effects on astrocytes and MCM-treated astrocytes (Fig. 2F ). zVAD-fmk (10 μM) also suppressed cytotoxicity induced by MCM of rat primary microglia (Suppl. Fig. 3 ).
NO influences glioma cell death
3-Morpholinosydnonimine (SIN-1) is a potent exogenous donor of peroxynitrite, a highly reactive molecule formed from NO in aqueous solutions [30] . Treatment of astrocytes or the glioma subconfluent monolayer with SIN-1 (0-1000 μM) for 72 h induced nitric oxide in a dose-dependent manner (Fig. 3A ). MTT and phenotypic results show that at these doses, SIN-1 does not significantly affect the cell viability of astrocytes ( Fig. 3B , phenotypic data not shown). In contrast, SIN-1 mediated cytotoxic effects in CRT-MG glioma cells at concentrations higher than 200 μM (Fig. 3B ) in a dose-dependent manner. Next, the effects of [N G -monomethyl-l-arginine(l-NMMA)], a NOS-specific inhibitor, were examined ( Fig. 3C ). After BV2 cells were stimulated with LPS with or without NMMA, MCM was prepared and applied to CRT-MG cells. Specifically, only glioma cell death by activated MCM was significantly suppressed in the presence of NMMA. The data clearly suggest that NO released by activated microglia plays a major role in glioma cytotoxicity.
Not only do activated microglia exhibit increased production of NO, they also produce increased levels of proinflammatory cytokines and chemokines. It has been suggested that microglia represent the first line of CNS defense against brain tumors by virtue of the cytotoxic potential of the proinflammatory cytokines, IL-1, IL-6, IL-10, TNF-α, and/or TGF-β [5] . In our supplementary experiments, we examined the effects of proinflammatory cytokines on glioma cell fate and found that treatment with cytokines, such as IL-1β, TNF-α, or IL-6, did not affect the viability of CRT-MG cells (Suppl. Fig. 4A ). Combined treatment with IL-1β, TNF-α, and IL-6 induced a modest decrease in cell viability, but significantly potentiated SIN-1-induced (100 and 200 μM) cytotoxicity (Suppl. Fig. 4B ).
2-D mapping to identify proteins secreted from BV2 for altered secretion patterns in the presence of LPS or IFN-γ and validation of 2-D mapping results by Western blotting
In order to identify proteins in MCM, microglial proteins secreted from non-treated control MCM and that stimulated by LPS or IFN-γ were separated on the basis of their own pI and molecular weight (MW) on a 2-D gel. MCM was collected, concentrated, precipitated with TCA, and subjected to 2-D gel electrophoresis (0.4 mg/gel). After colloidal Coomassie blue staining, over 200 protein spots were detectable on each 2-D gel. Protein spots that displayed altered secretion patterns in the presence of LPS and IFN-γ were selected using image analysis software, and subjected to MALDI-MS analysis. Some spots could not be characterized with MALDI-TOF due to insufficiencies or overlap. In total, 54 protein spots were identified (Table 1) . Swiss-Prot numbers of proteins displaying increased or decreased secretion following treatment with LPS and IFN-γ are labeled in red or blue, respectively (Fig. 4A ). Fig. 4B presents image analysis-based selection of apolipoprotein E (ApoE) (AAA37251) and cathepsin L (P06797) precursors as proteins displaying downregulated secretion in the presence of LPS and IFN-γ. The majority of secreted proteins were not altered in the presence of LPS and IFN-γ ( Fig. 4A ). Among these proteins, 33 were identified to indicate landmark proteins and normalize the level of protein secretion ( Table 1 ). The differential expression of a subset of identified proteins, such as ApoE, cathepsin L, and other cathepsin family proteases, was validated by Western blot analysis. Prior to Western blotting, silver staining of a SDS-PAGE gel was performed to detect protein patterns and confirm equivalent amounts of secreted protein (Suppl. Fig. 5 ). 2-D Western blotting for ApoE confirmed the presence of several subtypes or modified forms of ApoE proteins in MCM. Moreover, their levels were reduced in MCM preparations from LPS-or IFN-γ-stimulated microglia (Fig. 4C) . In contrast, the ApoE mRNA level was not affected by LPS or IFN-γ (Suppl. Fig. 6 ). ApoE and cathepsin L, A, B, and D protein levels were evaluated by Western blotting. Decreased secretion was observed in the presence of LPS and IFN-γ ( Fig. 4D) . Notably, these proteins were not detected in whole cell lysates, suggesting that they are truly secretory proteins. The decrease in the cathepsin L, B, and D proteins level as a result of LPS and IFN-γ treatment was additionally confirmed in primary microglial cells (Suppl. Fig. 7 ). HSP60 was strongly detected in whole cell lysates, compared to the low level detected in the secretory proteins ( Fig. 4D) . Ponceau staining and HSP60 immunoblotting revealed equivalent amounts of secretory and whole cell lysate proteins (Fig. 4D ).
Protease inhibitors, AEBSF, E-64, and LLnL, suppress microglia activation, and E-64 partially reverses MCM-induced cell death
We examined the effects of proteases on microglia behavior, and consequently, glioma cell death. The effects of a general serine protease inhibitor {4-(2-aminoethyl)benzenesulfonylfluoride (AEBSF)}, a cysteine protease inhibitor [31] , a cathepsin D inhibitor (pepstatin A), and a proteasome inhibitor {N-acetyl-L-leucyl-L-leucyl-L-norleucinal (LLnL)} on both microglia activation and MCM-induced glioma cell death were evaluated. Pretreatment of BV2 cells with AEBSF, E-64, or LLnL led to strong inhibition of mRNA induction of proinflammatory molecules, such as COX-2, IL-1β, TNF-α, and IL-6, as well as iNOS (Fig. 5A) . Consistent with this, AEBSF, E-64, and LLnL suppressed iNOS protein expression in BV2 cells (Fig. 5B) . The effects of AEBSF were further confirmed by suppression of NO release in a dose-dependent manner (Fig. 5C ). Similar inhibitory effects on NO release and activation-induced cell death were observed with E-64 and LLnL (data not shown).
Next, we examined whether AEBSF, E-64, or LLnL regulate glioma cell death mediated by microglia MCM. The serine protease inhibitor, AEBSF, had little effect on MCM-induced cell death (Fig. 5D ). Additionally, LLnL exerted no significant influence (data not shown). However, treatment with E64, a general cysteine protease inhibitor, which also acts on lysosomal cysteine cathepsins [32] , resulted in suppression of MCM- induced glioma cell death (Fig. 5D ). Unfortunately, this analysis was hampered since E-64 itself displayed some toxicity, particularly at higher concentrations (N15% cell death at doses higher than 5 μM).
Nevertheless, E-64 protected glioma cells from MCM-induced death.
The cathepsin B inhibitor, CA-074me, suppresses MCM-induced glioma cell death
We next addressed whether microglia-secreted cathepsins are essential in stimulating cytotoxicity in glioma cells. Neither microglial activation nor MCM-mediated cell death was influenced by cathepsin B, L, and S specific inhibitors, Z-FG-NHO-BzME, and Z-FG-NHO-Bz (data not shown). Moreover, immunodepletion of cathepsins with specific antibodies for cathepsin A, B, D, L, and K did not abolish the cytotoxic effects of MCM on CRT-MG glioma cells (data not shown). Strikingly, inhibition of the enzymatic activity of cathepsin B by CA-074me to MCM demonstrated inhibition of glioma cell death ( Fig. 6A and B) . CA-074me did not influence astrocyte either alone or in combination with MCM ( Fig. 6C) .
Importantly, general cysteine protease inhibitor, E-64, together with CA-074me displayed an additive effect on protection against MCMinduced glioma cell death (data not shown), indicating that other cysteine proteinases also can be involved in cytotoxicity. Direct treatment of CRT-MG with cathepsin B caused a decrease in cell survival (by ∼ 20%) (Fig. 6D) . These results strongly suggest that cathepsin B is an important mediator of MCM-induced glioma cell death.
Discussion
Since microglia produce and secrete various molecules in both the resting and activated states, microglia-mediated responses to brain tumors may be broadly influenced by secreted soluble factors. The microglial soluble factor(s) involved in glioma proliferation or death remain to be identified. In this report, we show that substance(s) released by microglia induce apoptosis of astrocytic glioma cells. Significantly, the cytotoxic effects of MCM were specific for astrocytic glioma cells, since primary cultured astrocyte survival was not influenced. In fact, MCM induced mild, but consistent proliferation of astrocytes (data not shown). This selective cytotoxic effect was enhanced upon microglial activation.
The viability of glioma cells was remarkably decreased in the presence of SIN-1 at concentrations of 400-1000 μM, which usually releases about 20-40 μM nitrite into culture medium at 72 h. In contrast, astrocytes were resistant to SIN-1, even at 1000 μM. The data suggest that activated microglia selectively induce glioma cell apoptosis by activating iNOS and subsequent release of NO. Furthermore, we also found that combined treatment with IL-1β, TNF-α, and IL-6 significantly potentiated SIN-1-induced cytotoxicity.
Thus, our report provides new information, demonstrating that microglial-secreted NO acts in concert with proinflammatory cytokines to play an important role in regulating tumor growth.
NO effect was insufficient to explain glioma cell death by MCM. MCM induced significant cell death, despite the presence of very low levels of NO. Furthermore, inclusion of NOS inhibitors into microglia culture led to significant suppression of glioma cell death mediated by activated MCM, but not by MCM. Thus, it is likely that NO in the activated MCM is the principal cytotoxic mediator of glioma, while cathepsin B released by microglia in the resting state may be critical in the induction of glioma cytotoxicity. One issue for consideration is that depletion of nutrients or energy sources in the culture medium elicits apoptosis of glioma cells. To eliminate this possibility, we added pyruvate (2 mM) to the culture medium as an energy source, which did not affect glioma apoptosis (data not shown). In addition, conditioned culture medium prepared similarly from other cells (rat2 mouse fibroblasts or A549 lung adenocarcinoma cells) elicited no significant effects on glioma cell survival or proliferation (data not shown). Furthermore, conditioned media from rat2 mouse fibroblasts or A549 lung adenocarcinoma cells stimulated with LPS or IFN-γ did not induce any influences on glioma cell survival/proliferation (data not shown). Nonetheless, there is no evidence to rule out the possibility of depletion of critical factor(s) required for glioma survival in MCM.
To identify the proteins secreted by microglia and compare their expression patterns in the unstimulated and stimulated states, we established 2-D maps of BV2 microglia secretory proteins obtained from either control MCM or MCM stimulated by LPS or IFN-γ. Notably, apolipoprotein E (ApoE) and cathepsin proteases displayed the most marked alterations in the presence of LPS and IFN-γ. Our finding that ApoE is down-regulated in BV2 MCM treated with LPS and IFN-γ is consistent with previous reports [33, 34] . Moreover, the low level of endogenous ApoE in non-treated and LPS-and IFN-γ-treated cells suggests that either secretion or protein expression of ApoE is regulated. Since the mRNA level of ApoE was not changed by LPS or IFN-γ, we hypothesize that the secretion phase or protein stability is regulated. Immunodepletion of ApoE using specific antibodies did not influence MCM-mediated apoptosis of glioma (data not shown). In addition, exogenous ApoE4 did not induce phenotypic or cytotoxic effects on glioma cells (data not shown), ruling out its direct involvement in glioma cell survival. While the effects of other isoforms of ApoE (ApoE2 and ApoE3) remain to be established, current data suggest that the protein does not have a critical function in microglia-mediated cytotoxicity of glioma cells.
In our experiments, secretion of several lysosomal cathepsin proteases (A, B, D, and L) was suppressed by LPS or IFN-γ. In contrast to our findings, up-regulated extracellular accumulation of cathepsin L has been reported in IFN-γ-treated macrophages and LPS-activated dendritic cells [35] . In addition, treatment of human U-937 monocytes and macrophages with IFN-γ leads to an increase in the activity and content of cathepsins B and L [35, 36] . These inconsistent results may reflect the characteristics of microglia response in neuroinflammation processes and various neuronal diseases. Up-regulated extracellular accumulation of cathepsin D has been also reported in LPS/IFN-γtreated BV2 cells [37] . While the reason for the discrepancy in response between LPS or IFN-γ and LPS plus IFN-γ for cathepsin D release remains to be elucidated, one possibility includes that combinatory signals from LPS and IFN-γ are required for increased expression of cathepsin D. Among the cathepsin proteins, the importance of cathepsin B in inflammation-related cytotoxicity has been extensively examined. E-64 and CA-074me [32, 38] , inhibitors for cathepsin B, significantly suppressed glioma apoptosis. In view of these results, we propose that cathepsin B is a critical factor in MCMmediated glioma death. The purified cathepsin B induced significant but relatively mild cytotoxic effect on glioma (∼ 20% reduction in cell viability). This may be due to the relatively weak biological effect of purified cathepsin B compared to endogenous proteins or the potential presence of a critical regulator or cofactor of cathepsin B in MCM. Accumulating knowledge on proteolytic events and subsequent effects in brain inflammation and cell death mediated by microglial proteases will not only contribute to a better understanding of the role of microglial-secreted proteins in the CNS but also aid in the development of protease inhibitors as novel neuroprotective or neuro-immunoregulatory agents. Given the dynamic regulation of microglia-secreted proteins, characterization of the functions of other cathepsin proteins (A, D, K, L, and Z) in brain physiology and pathology is essential. It has been shown that microglial produced MMP-3 or -9 are involved in microglial activation [39, 40] . While the roles of MMPs in glioma invasion are described in many reports, few studies focused on apoptotic effects of MMPs to glioma cells. Our proteomic data did not show any evidences for (changed) expression of MMPs in BV2 conditioned medium.
To date, 2-D-based proteome mapping has been limited to the detection of large proteins or relatively high concentrations of proteins. Thus, low abundance proteins have undoubtedly been overlooked due to the inadequate sensitivity of Coomassie blue staining. Future laboratory analyses will employ fluorescent stains or isotope labeling, which should allow the efficient analysis of less abundant proteins.
In conclusion, our results support the idea that microglia play an active role in the regulation of tumor cell death by local secretion of NO and cathepsin B. It is currently unclear how exogenous cathepsin B initiates or propagates proapoptotic signals. One possibility includes that cathepsin B could nonspecifically degrade important cell surface proteins, thereby causing the cell to initiate apoptosis. Alternatively, cathepsin B could cleave extracellular matrix proteins, which are important for cell survival, thereby causing apoptosis. We expect that future studies aimed at identifying the downstream targets of cathepsin B effects will contribute to the understanding of microglial produced proteases in pathogenesis of brain tumor. Because microglial secretion of these molecules is dynamically regulated by stimulation with LPS or IFN-γ, the modulation of microglial activation may contribute to the control of brain neoplasms.
